Skip to main content
SpringerLink
Log in

Simultane Radiochemotherapie mit 5-FU/Mitomycin bleibt bei Behandlung von Analkanalkarzinomen der bevorzugte Standard

Langzeitergebnisse der Phase-III-Studie RTOG 98-11

Concurrent radiochemotherapy with 5-FU/mitomycin remains standard treatment for anal carcinoma

Long-term results of the phase III RTOG 98-11 trial

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Brooks CJ, Lee YK, Aitken K et al (2012) Organ-sparing intensity-modulated radiotherapy for anal cancer using the ACTII schedule: a comparison of conventional and intensity-modulated radiotherapy plans. Clin Oncol (R Coll Radiol) 5:155–161

    Google Scholar 

  2. Fakhrian K, Sauer T, Klemm S et al (2013) Radiotherapy with or without chemotherapy in the treatment of anal cancer: 20-year experience from a single institute. Strahlenther Onkol 189:18–25

    Article  PubMed  CAS  Google Scholar 

  3. Gunderson LL, Winter KA, Ajani JA et al (2012) Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol 30:4344–4351

    Article  PubMed  CAS  Google Scholar 

  4. Kachnic LA, Winter K, Myerson RJ et al (2012) RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys (Epub ahead of print) doi:10.1016/j.ijrobp.2012.09.023

    Google Scholar 

  5. Peiffert D, Tournier-Rangeard L, Gérard JP et al (2012) Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol 30:1941–1948

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology and Palliative Medicine, Nordland Hospital, 8092, Bodø, Norwegen

    C. Nieder

Authors
  1. C. Nieder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Nieder.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nieder, C. Simultane Radiochemotherapie mit 5-FU/Mitomycin bleibt bei Behandlung von Analkanalkarzinomen der bevorzugte Standard. Strahlenther Onkol 189, 512–513 (2013). https://doi.org/10.1007/s00066-013-0335-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-013-0335-0

Search

Navigation